<SEC-DOCUMENT>0001144204-16-094104.txt : 20160413
<SEC-HEADER>0001144204-16-094104.hdr.sgml : 20160413
<ACCEPTANCE-DATETIME>20160413160635
ACCESSION NUMBER:		0001144204-16-094104
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160411
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160413
DATE AS OF CHANGE:		20160413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53121
		FILM NUMBER:		161569336

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v436881_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B><BR>
<B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<U>April 11, 2016</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">AYTU BIOSCIENCE, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Exact Name of Registrant as Specified in Charter)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Delaware</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">000-53121</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">47-0883144</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or Other Jurisdiction<BR>
of Incorporation)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission<BR>
File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(IRS Employer<BR>
Identification No.)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">373 Inverness Parkway, Suite 206, Englewood, Colorado</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">80112</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s Telephone Number, Including
Area Code: <U>(720) 437-6580</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%"><B>Item&nbsp;5.02.&nbsp;&nbsp;</B></TD>
    <TD STYLE="padding-left: 6.3pt; text-indent: -6.3pt"><B>Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-indent: 31.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-indent: 31.7pt">Effective April 11, 2016, our
Board appointed Carl C. Dockery as a director, to hold office until our next annual meeting of stockholders, which is scheduled
for May 24, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr.&nbsp;Dockery is a financial executive
with 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the founder
and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr.&nbsp;Dockery&rsquo;s career as an insurance executive
began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of
Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London
reinsurance market, in the 1990s, Mr.&nbsp;Dockery worked at Lloyd&rsquo;s and the London Underwriting Centre brokering various
types of reinsurance placements. Mr. Dockery serves as a director of CytoDyn Inc. (OTCQB: &ldquo;CYDY&rdquo;), a biotechnology
company. Mr.&nbsp;Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no arrangements or understandings
between Mr. Dockery and any other person pursuant to which Mr. Dockery was appointed to the Board and there are no related party
transactions between Mr. Dockery and Aytu.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with his appointment to the
Board, we granted Mr. Dockery options to purchase 100,000 shares of our common stock. The options vested upon grant and have an
exercise price of $0.56 per share, which was the closing price of Aytu common stock on April 11, 2016, as reported on the OTCQX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press release announcing the
appointment of Mr. Dockery is attached hereto as Exhibit 99.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 9.01. Financial Statements and Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 15%">(d)</TD>
    <TD STYLE="width: 79%">Exhibits</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-decoration: underline"><U>Exhibit No.</U></TD>
    <TD STYLE="text-decoration: underline"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>99.1</TD>
    <TD>Press Release dated April 13, 2016. </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SIGNATURE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date: April 13, 2016</TD>
    <TD STYLE="width: 50%">AYTU BIOSCIENCE, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-decoration: underline"><U>/s/ Gregory A. Gould&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Gregory A. Gould</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v436881_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 60pt; width: 142.5pt"><BR>
<BR>
<B>Aytu BioScience Strengthens Board with Appointment of First Independent Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Veteran Financial Executive Carl Dockery
Joins Aytu</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Englewood, CO &ndash; April 13, 2016 &ndash; Aytu BioScience,
Inc.</B> (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, announced
today the appointment of Carl Dockery, a 30-year financial veteran with biopharma board experience, to serve on Aytu&rsquo;s Board
of Directors. Mr. Dockery brings significant financial and independent leadership insight to the Company, joining current Board
members Josh Disbrow, Aytu CEO; Jarrett Disbrow, Aytu COO; and Michael Macaluso, Chairman and CEO of Ampio Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Josh Disbrow, Chief Executive Officer of Aytu, stated, &ldquo;We
have accelerated Aytu&rsquo;s operations in a short amount of time, building a growing, global urology-focused portfolio of commercial
products. Establishing a strong Board of Directors is instrumental in maintaining our substantial growth trajectory. As we continue
to expand our urology-focused organization, we look forward to Carl&rsquo;s leadership and insight as an independent director in
helping to generate value for Aytu shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Dockery commented, &ldquo;As a healthcare investor, I recognize
the potential for Aytu to rapidly establish itself as a leader in the specialty pharmaceutical industry through its proven commercial-focused
business strategy. I&rsquo;m pleased to join the company as it executes multiple product launches and to help guide the continued
expansion of Aytu&rsquo;s infrastructure and portfolio in line with its growth objectives.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carl Dockery is a financial executive with 30 years of experience
in the insurance and reinsurance industry, more recently as the founder of a registered investment advisory firm, Alpha Advisors,
LLC in 2006. Carl's career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance
companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as Vice President of Gulf Insurance Co.
Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd's and the London Underwriting
Centre brokering various types of reinsurance placements. Carl is currently a member of the Board of Directors of CytoDyn, Inc.,
a publicly traded biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal
antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection and is an active investor in various
healthcare companies through Alpha Ventures, the venture capital affiliate of Alpha Advisors. Mr. Dockery graduated from Southeastern
University with a Bachelor of Arts in Humanities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aytu BioScience, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioScience is a commercial-stage specialty healthcare company
focused on global commercialization of novel products in the field of urology. Aytu&rsquo;s current portfolio of commercial and
late-stage urology products addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction,
and the company plans to expand into other urological indications for which there are significant medical needs. The company currently
markets ProstaScint&reg; (capromab pendetide), the only radio-labeled monoclonal antibody that targets prostate specific membrane
antigen (PSMA), a protein highly expressed by prostate cancer cells. ProstaScint is FDA-approved as an imaging agent for use in
both newly diagnosed, high-risk prostate cancer patients and patients with recurrent prostate cancer. Aytu also markets Primsol&reg;
(trimethoprim hydrochloride) &ndash; the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Additionally,
Aytu markets the CE Marked MiOXSYS&trade; System outside the U.S. and is conducting U.S.-based clinical trials, following which
the company plans to seek 510k de novo medical device clearance. The MiOXSYS System is a novel, rapid semen analysis system with
the potential to become a standard of care in the diagnosis and management of male infertility. MiOXSYS is the only rapid test
for assessing oxidative stress in semen and seminal plasma, a leading contributor of idiopathic male infertility. Aytu&rsquo;s
strategy is to continue building its portfolio of revenue-generating urology products and late-stage development assets, leveraging
its commercial team and expertise to further build those brands within well-established markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Investors &amp; Media:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiberend Strategic Advisors, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Janine McCargo: jmccargo@tiberend.com; (646) 604-5150</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or
the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements
regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives
of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future
tense and/or are preceded by words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;suggest,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; or similar words, or the negatives of such terms or other variations
on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that
could cause the actual events or results to differ materially. These risks and uncertainties include, among others: our plans to
expand our board of directors and infrastructure; our plans for product growth, expansion and acquisition; the anticipated start
dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials; risks
relating to gaining market acceptance of our products; obtaining reimbursement by third-party payors; the potential future commercialization
of our product candidates; the anticipated designs of our future clinical trials; anticipated future regulatory submissions and
events; our anticipated future cash position; and future events under our current and potential future collaborations. We also
refer you to the risks described in &ldquo;Risk Factors&rdquo; in Part I, Item 1A of Aytu BioScience, Inc.&rsquo;s Annual Report
on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 +X# 2(  A$! Q$!_\0
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MQ%:1YEMP([H*/O)GAOP)P?8^U=6&J\LN7N>?F&&56'-;5'FEHPO9$C@^9W(
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M3YBJ!D9P,]3BK]I=1WMI%<PDF.50PSUH FHHHH **** "BBB@ HHHH ****
M"BBB@"AK-E)J.D7%I"R+)(  7) Z@U6FLM1O[FU-T+2&&WF6;]TS.S$=LD#
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6K%Y%K''Y<494<I",(#WQ[5-10!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
